BRAIN and NERVE－神経研究の進歩68巻7号

2016年07月発行

増大特集 認知症の危険因子と防御因子

脂質異常症と認知症

著者： 玉岡晃¹

所属機関： ¹筑波大学医学医療系神経内科学

ページ範囲：P.737 - P.742

文献概要

中年期のコレステロールの高値が老年期のアルツハイマー病（AD）の危険因子となることを示唆する多くの疫学的知見が報告されているが，スタチンのAD発症抑制効果については議論のあるところである。スタチンはin vitroでは脳内アミロイドβ蛋白を減少させる効果が報告されており，ADに対するスタチンの効果については，早期からのスタチンの投与による臨床経過，各種心理テスト，ADサロゲートマーカーへの影響を含めた包括的な検討が必要である。

参考文献

1)Ferri CP, Prince M, Brayne C, Brodaty H, Fratiglioni L, et al: Global prevalence of dementia: a Delphi consensus study. Lancet 366: 2112-2117, 2005

2)Fotuhi M, Hachinski V, Whitehouse PJ: Changing perspectives regarding late-life dementia. Nat Rev Neurol 5: 649-658, 2009

3)Iadecola C: The overlap between neurodegenerative and vascular factors in the pathogenesis of dementia. Acta Neuropathol 120: 287-296, 2010

4)de la Torre JC: Is Alzheimer's disease a neurodegenerative or a vascular disorder? Data, dogma, and dialectics. Lancet Neurol 3: 184-190, 2004

5)Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, et al; American Heart Association Stroke Council, Council on Epidemiology and Prevention, Council on Cardiovascular Nursing, Council on Cardiovascular Radiology and Intervention, and Council on Cardiovascular Surgery and Anesthesia: Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the American heart association/American stroke association. Stroke 42: 2672-2713, 2011

6)Carlsson CM: Type 2 diabetes mellitus, dyslipidemia, and Alzheimer's disease. J Alzheimers Dis 20: 711-722, 2010

7)Panza F, Frisardi V, Seripa D, Imbimbo BP, Sancarlo D, et al: Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res 8: 492-509, 2011

8)Kloppenborg RP, van den Berg E, Kappelle LJ, Biessels GJ: Diabetes and other vascular risk factors for dementia: which factor matters most? A systematic review. Eur J Pharmacol 585: 97-108, 2008

9)Shoji T, Hatsuda S, Tsuchikura S, Shinohara K, Kimoto E, et al: Small dense low-density lipoprotein cholesterol concentration and carotid atherosclerosis. Atherosclerosis 202: 582-588, 2009

10)Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, et al: Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32: 169-174, 2009

11)Perlmuter LC, Nathan DM, Goldfinger SH, Russo PA, Yates J, et al: Triglyceride levels affect cognitive function in noninsulin-dependent diabetics. J Diabet Complications 2: 210-213, 1988

12)Fonseca AC, Resende R, Oliveira CR, Pereira CM: Cholesterol and statins in Alzheimer's disease: current controversies. Exp Neurol 223: 282-293, 2010

13)Bonarek M, Barberger-Gateau P, Letenneur L, Deschamps V, Iron A, et al: Relationships between cholesterol, apolipoprotein E polymorphism and dementia: a cross-sectional analysis from the PAQUID study. Neuroepidemiology 19: 141-148, 2000

14)Razay G, Vreugdenhil A, Wilcock G: The metabolic syndrome and Alzheimer disease. Arch Neurol 64: 93-96, 2007

15)Reitz C: Dyslipidemia and the risk of Alzheimer's disease. Curr Atheroscler Rep 15: 307, 2013

16)Shepardson NE, Shankar GM, Selkoe DJ: Cholesterol level and statin use in Alzheimer disease: Ⅱ. Review of human trials and recommendations. Arch Neurol 68: 1385-1392, 2011

17)Notkola IL, Sulkava R, Pekkanen J, Erkinjuntti T, Ehnholm C, et al: Serum total cholesterol, apolipoprotein E ε4 allele, and Alzheimer's disease. Neuroepidemiology 17: 14-20, 1998

18)Kivipelto M, Helkala EL, Laakso MP, Hänninen T, Hallikainen M, et al: Apolipoprotein E epsilon4 allele, elevated midlife total cholesterol level, and high midlife systolic blood pressure are independent risk factors for late-life Alzheimer disease. Ann Intern Med 137: 149-155, 2002

19)Launer LJ, White LR, Petrovitch H, Ross GW, Curb JD: Cholesterol and neuropathologic markers of AD: a population-based autopsy study. Neurology 57: 1447-1452, 2001

20)Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, et al: Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61: 199-205, 2003

21)Whitmer RA, Sidney S, Selby J, Johnston SC, Yaffe K: Midlife cardiovascular risk factors and risk of dementia in late life. Neurology 64: 277-281, 2005

22)Reitz C, Tang MX, Luchsinger J, Mayeux R: Relation of plasma lipids to Alzheimer disease and vascular dementia. Arch Neurol 61: 705-714, 2004

23)Romas SN, Tang MX, Berglund L, Mayeux R: APOE genotype, plasma lipids, lipoproteins, and AD in community elderly. Neurology 53: 517-521, 1999

24)Kuusisto J, Koivisto K, Mykkänen L, Helkala EL, Vanhanen M, et al: Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 315: 1045-1049, 1997

25)Li G, Shofer JB, Kukull WA, Peskind ER, Tsuang DW, et al: Serum cholesterol and risk of Alzheimer disease: a community-based cohort study. Neurology 65: 1045-10450, 2005

26)Slooter AJC, Ruitenberg A, van Duijn CM, Breteler MMB: The effect of apoE on dementia is not through atherosclerosis: The Rotterdam Study［Reply from authors］. Neurology 54: 2357-2358, 2000

27)Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA: Statins and the risk of dementia. Lancet 356: 1627-1631, 2000

28)Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G: Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57: 1439-1443, 2000

29)Yaffe K, Barrett-Connor E, Lin F, Grady D: Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59: 378-384, 2002

30)Wolozin B, Wang SW, Li NC, Lee A, Lee TA, et al: Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 5: 20, 2007

31)Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM: Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80: 13-17, 2009

32)Li G, Larson EB, Sonnen JA, Shofer JB, Petrie EC, et al: Statin therapy is associated with reduced neuropathologic changes of Alzheimer disease. Neurology 69: 878-885, 2007

33)Zandi PP, Sparks DL, Khachaturian AS, Tschanz J, Norton M, et al: Do statins reduce risk of incident dementia and Alzheimer disease? The Cache County study. Arch Gen Psychiatry 62: 217-224, 2005

34)Rea TD, Breitner JC, Psaty BM, Fitzpatrick AL, Lopez OL, et al: Statin use and the risk of incident dementia. The cardiovascular health study. Arch Neurol 62: 1047-1051, 2005

35)Arvanitakis Z, Schneider JA, Wilson RS, Bienias JL, Kelly JF, et al: Statins, incident Alzheimer disease, change in cognitive function, and neuropathology. Neurology 70: 1795-1802, 2008

36)Friedhoff LT, Cullen EI, Geoghagen NSM, Buxbaum JD: Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide. Int J Neuropsychopharmacol 4: 127-130, 2001

37)Sparks DL, Sabbagh MN, Connor DJ, Lopez J, Launer LJ, et al: Atorvastatin for the treatment of mild to moderate Alzheimer disease: preliminary results. Arch Neurol 62: 753-757, 2005

38)Shepherd J, Blauw GJ, Murphy MB, Bollen EL, Buckley BM, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk: Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 360: 1623-1630, 2002

39)Heart Protection Study Collaborative Group: MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 7-22, 2002

40)Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, et al; LEADe Investigators: Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74: 956-964, 2010

41)Sano M, Bell KL, Galasko D, Galvin JE, Thomas RG, et al: A randomized, double-blind, placebo-controlled trial of simvastatin to treat Alzheimer disease. Neurology 77: 556-563, 2011

42)Richardson K, Schoen M, French B, Umscheid CA, Mitchell MD, et al: Statins and cognitive function: a systematic review. Ann Intern Med 159: 688-697, 2013

43)Song Y, Nie H, Xu Y, Zhang L, Wu Y: Association of statin use with risk of dementia: a meta-analysis of prospective cohort studies. Geriatr Gerontol Int 13: 817-824, 2013

44)Wong WB, Lin VW, Boudreau D, Devine EB: Statins in the prevention of dementia and Alzheimer's disease: a meta-analysis of observational studies and an assessment of confounding. Pharmacoepidemiol Drug Saf 22: 345-358, 2013

45)McGuinness B, O'Hare J, Craig D, Bullock R, Malouf R, et al: Cochrane review on ‘Statins for the treatment of dementia.’ Int J Geriatr Psychiatry 28: 119-126, 2013

46)Kuo YM, Emmerling MR, Bisgaier CL, Essenburg AD, Lampert HC, et al: Elevated low-density lipoprotein in Alzheimer's disease correlates with brain Aβ 1-42 levels. Biochem Biophys Res Commun 252: 711-715, 1998

47)Okamura N, Arai H, Maruyama M, Matsui T, Tanji H, et al: Serum cholesterol and cerebrospinal fluid amyloid β protein in Alzheimer's disease. J Am Geriatr Soc 49: 1738-1739, 2001

48)Engelhart MJ, Geerlings MI, Ruitenberg A, Van Swieten JC, Hofman A, et al: Diet and risk of dementia: Does fat matter?: The Rotterdam study. Neurology 59: 1915-1921, 2002

49)Simons M, Keller P, De Strooper B, Beyreuther K, Dotti CG, et al: Cholesterol depletion inhibits the generation of β-amyloid in hippocampal neurons. Proc Natl Acad Sci U S A 95: 6460-6464, 1998

50)Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F: Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the α-secretase ADAM 10. Proc Natl Acad Sci U S A 98: 5815-5820, 2001

51)Urano Y, Hayashi I, Isoo N, Reid PC, Shibasaki Y, et al: Association of active γ-secretase complex with lipid rafts. J Lipid Res 46: 904-912, 2005

52)Fassbender K, Simons M, Bergmann C, Stroick M, Lutjohann D, et al: Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci U S A 98: 5856-5861, 2001

53)Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, et al: A cholesterol-lowering drug reduces β-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8: 890-899, 2001

54)Hosaka A, Araki W, Oda A, Tomidokoro Y, Tamaoka A: Statins reduce amyloid β-peptide production by modulating amyloid precursor protein maturation and phosphorylation through a cholesterol-independent mechanism in cultured neurons. Neurochem Res 38: 589-600, 2013

55)Tokuda T, Tamaoka A, Matsuno S, Sakurai S, Shimada H, et al: Plasma levels of amyloid β proteins did not differ between subjects taking statins and those not taking statins. Ann Neurol 49: 546-547, 2001

56)Ishii K, Tokuda T, Matsushima T, Miya F, Shoji S, et al: Pravastatin at 10 mg/day does not decrease plasma levels of either amyloid-β (Aβ) 40 or Aβ 42 in humans. Neurosci Lett 350: 161-164, 2003

57)Friedhoff LT, Cullen EI, Geoghagen NS, Buxbaum JD: Treatment with controlled-release lovastatin decreases serum concentrations of human β-amyloid (Aβ) peptide. Int J Neuropsychopharmacol 4: 127-130, 2001